---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007978"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:09:59.515312+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protalix Q1 net loss $3.1M on revenue decline; positive CHMP opinion for PRX-102

## Summary
- Revenue from goods fell 43% to $5.1M; license and R&D revenue down 37% to $4.5M.
- Net loss of $3.1M ($0.05/sh) vs $2.3M loss in Q1 2022; cash $33.0M.
- Feb 24, 2023: CHMP positive opinion recommending EU approval of PRX-102 for Fabry disease.
- First patient dosed in Phase I trial of PRX-115 (PEGylated uricase) for severe gout.
- Voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023.

## SEC filing metadata
- accession: 0001558370-23-007978
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/0001558370-23-007978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/plx-20230504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007978
- JSON: https://secwatch.observer/filing/0001558370-23-007978.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007978.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million, net income Net loss of approximately $3.1 million, EPS loss of $0.05 per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million
  - Net income: Net loss of approximately $3.1 million
  - EPS: loss of $0.05 per share
  - Result: reported results
  source text: First Quarter 2023 Financial Highlights ● The Company recorded revenues from selling goods of $5.1 million during the three months ended March 31, 2023, a decrease of $3.9 million, or 43%, compared to revenues of $9.0 million for the three months ended March 31, 2022. The decrease resulted primarily from a decrease of $2.7 million in sales to Brazil and a decrease of $1.1 million in sales to Pfizer, both resulting from timing differences. ● The Company recorded revenues from license and R&D services of $4.5 million for the three months ended March 31, 2023, a decrease of $2.6 million, or 37%, compared to revenues of $7.1 million for the three months ended March 31, 2022. Revenues from license and R&D services are comprised primarily of revenues the Company recognized in connection with the Chiesi Agreements. ● Cost of goods sold was $3.1 million for the three months ended March 31, 2023, a decrease of $2.9 million, or 48%, from cost of goods sold of $6.0 million for the three months en
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/0001558370-23-007978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.